Anacor Pharmaceuticals to Present New Data on AN2728 and GSK ?052 at Upcoming Meetings
PALO ALTO, Calif.--(BUSINESS WIRE)--Apr 18, 2011 - Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it will present data on two of its compounds at the following conferences:
- 2011 Society for Investigative
Dermatology (SID) Annual Meeting
- Lee Zane, M.D., Anacor's Chief Medical Officer, will present “Safety and efficacy of AN2728 ointment in a phase 2b dose-ranging bilateral study of mild-to-moderate plaque psoriasis” in a poster session on Thursday May 5, 2011 at 10 a.m. MT / 9 a.m. PT.
- 21st European Congress of
Clinical Microbiology and Infectious Diseases
- Liang Liu, Senior Director of Pharmacokinetics and Drug Metabolism, will present “Interspecies scaling for prediction of human intravenous pharmacokinetics of GSK2251052 (GSK ˜052), a novel boron-based antimicrobial against Gram-negative bacteria” in poster topic 17 on Saturday May 7, 2011 at 3:30 p.m. CET / 6:30 a.m. PT.
- Dr. Zane will present “Safety, tolerability, and pharmacokinetics of a novel Gram-negative antimicrobial, GSK2251052 (GSK ˜052), in healthy subjects” in poster topic 65 on Monday May 9, 2011 at 12:30 p.m. CET / 3:30 a.m. PT.
Posters from the presentations will be available at the time of each session on Anacor's website at www.anacor.com.
AN2728 is a topical anti-inflammatory product candidate for the treatment of psoriasis. Psoriasis is a chronic inflammatory skin disease that affects approximately 7.5 million people in the United States and over 100 million people worldwide. AN2728 is a boron-based small-molecule compound which inhibits the activity of phosphodiesterase-4 (PDE4), thereby reducing the production of TNF-alpha, IL-12, IL-23 and other pro-inflammatory cytokines that are the precursors of the inflammation associated with psoriasis. AN2728 is currently in its final Phase 2b study, a double-blind, randomized, vehicle-controlled trial with data expected in mid-2011.
About GSK ˜052
GSK ˜052 is a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria. Gram-negative bacterial infections are increasing in prevalence, especially in hospitals, and represent a serious public health challenge due to their growing resistance to currently available drug therapies. Gram-negative bacteria are responsible for more than 30.0% of hospital-acquired infections and account for approximately 70.0% of hospital-acquired infections in the intensive care unit. Following the completion of the Phase 1 trial, GSK exercised its option to obtain an exclusive license to develop and commercialize GSK ˜052 and has assumed responsibility for further development of the product candidate and any resulting commercialization.
About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered five clinical compounds that are currently in development, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis; and GSK 2251052, or GSK ˜052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline under the companies' research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis. For more information visit http://www.anacor.com.
Contact: Anacor Pharmaceuticals, Inc.
DeDe Sheel, 650-543-7575
Director, Investor Relations and Corporate Communications
Posted: April 2011